Eschewing the traditional model of financing biotech startups milestone to milestone to support a lead asset, Treeline Biosciences’ well-funded pipeline is comprised of multiple complementary programs. Select investors have supported the approach of Treeline, which said it has raised more than $1.1 billion to date.
The post Startup Treeline Bio Emerges From the Shadows With $1B+ Raised and 3 Cancer Drugs in the Clinic appeared first on MedCity News.
